Background: We evaluated the effectiveness of targeted antimicrobial prophylaxis in transrectal ultrasound guided prostate biopsy (TRUSP).
Background
More than two million transrectal ultrasound guided prostate biopsies (TRUSP) are performed in the US and Europe annually [1, 2] . Infectious complications range from uncomplicated urinary tract infections (UTIs) to prostatitis to sepsis and death [3] . Empiric antimicrobial prophylaxis reduced the risk of infectious complications [4] but, with increasing resistance, infections after biopsy have risen [1, [5] [6] [7] [8] [9] and are most commonly fluoroquinolone (FQ)-resistant (R) gram-negative bacteria (GNB) [10] .
Two primary prophylaxis strategies have emerged to prevent post-biopsy infections, a targeted or an empiric approach [7, [11] [12] [13] . The targeted approach involves obtaining a pre-biopsy rectal swab culture and choosing an antimicrobial agent based on culture results. The empiric approach is frequently based on local antibiograms [7, 12, [14] [15] [16] . Both approaches can be augmented by adding an antimicrobial agent to a fluoroquinolone or combination non-quinolone based regimen. To date, although studies have shown significant reduction in infectious complications, these studies may have been subject to underreporting because they were retrospective [5, 12, 14, 15] , did not use phone contact for follow-up [7, [12] [13] [14] [15] [16] , did not report non-hospitalized infections [7, 11, 12] , and followed patients for less than 30 days [11, 16] . Additionally, the augmented approach introduces the concern for driving further antimicrobial resistance [17] .
In our study, we prospectively evaluated patients by phone interview at 7 and 30 days to evaluate the rate of all post-biopsy infections in our patients treated with targeted prophylaxis based on rectal swab culture. Targeted antimicrobial prophylaxis achieved a low rate of infectious complications, limited morbidity and no sequelae in patients with either ciprofloxacin-susceptible or -resistant gram-negative rectal flora. These results suggest that this individualized method of prophylaxis may be widely applied.
Methods

Study setting and design
The study was conducted in the Northwestern University (NU) Feinberg School of Medicine Department of Urology at Northwestern Memorial Hospital between November 1, 2012 and March 31, 2015 . This prospective, non-randomized cohort trial evaluated the efficacy of targeted pre-procedural antimicrobial prophylaxis for TRUSP and tested the hypothesis that infectious complication rates for targeted prophylaxis in patients with ciprofloxacin-susceptible compared to ciprofloxacin-resistant gram-negative bacteria (CS-GNB and CR-GNB, respectively) rectal flora would be equivalent. The Institutional Review Board of NU approved this study.
Recruitment and eligibility criteria
Eligible patients were men 18 years or older selected to undergo TRUSP to evaluate for prostate cancer. Patients were excluded from the study if (1) they did not complete or withdrew informed consent; (2) their rectal swab cultures were CS-GNB but they did not receive ciprofloxacin as pre-procedure prophylaxis (i.e. ciprofloxacin-allergic patients); (3) their rectal swab cultures showed CR-GNB but they received ciprofloxacin; or (4) they did not complete the pre-biopsy questionnaire or the two post-biopsy phone screening evaluations. Of the 510 study participants, 26, who fulfilled eligibility criteria but received augmented prophylaxis (24 empiric, 2 directed) at the discretion of the treating physician, were evaluated in a separate intention-to-treat (ITT) analysis.
Clinical specimen processing
After completing a pre-biopsy questionnaire (Additional file 1) to record demographics and to evaluate risk factors for infection, all subjects had rectal swab cultures obtained no more than 30 days prior to the TRUSP (Additional file 2). Swabs were cultured on blood agar and on MacConkey agar supplemented with 1 μg/ml ciprofloxacin (Thermo Scientific™ Remel™, Waltham, MA, USA). Quality control (QC) was performed on each new lot and shipment of MacConkey agar according to manufacturer's instructions [18] . The following QC strains were utilized: Staphylococcus aureus ATCC® 25,923; Pseudomonas aeruginosa ATCC® 27,853; Escherichia coli ATCC® 25,922; and Escherichia coli strain #OC110. The plates were placed in a CO 2 incubator (35°to 37°C) and read at 36-48 h.
Bacterial species identification and antimicrobial susceptibility testing
Blood agar plates without growth indicated inadequate specimen collections. Specimens with growth on blood agar only were considered to contain CS-GNR. Specimens with growth of gram-negative rods (GNRs) on blood and supplemented MacConkey agar underwent organism identification and antimicrobial susceptibility testing using an automated microbial system (Vitek® 2, Biomérieux, Durham, NC, USA) using the AST-GN47 cards. Antimicrobial susceptibilities were reported according to Clinical Laboratory Standards Institute (CLSI) guidelines [19] .
Selection of antimicrobial prophylaxis
Prophylactic antimicrobial agents were selected using a pre-determined protocol (Additional file 3). Patients with CS-GNR received ciprofloxacin 500 mg orally 2 h before TRUSP and 500 mg orally 12 h later. Subjects harboring CR-GNB received an antimicrobial agent based on the AUA guidelines (Additional file 3). Selection of the narrowest spectrum agent available was encouraged. Twenty-six patients (24 CS, 2 CR) received targeted prophylaxis augmented by another antimicrobial at the discretion of the treating physician based on the patient's clinical status.
Clinical evaluation
The data were derived from the pre-biopsy questionnaire and electronic medical record review. Charlson score was calculated by ICD-9 codes [20] . Immediately prior to the biopsy, enema and antimicrobial prophylaxis, including drug, dose, and timing, were confirmed. Phone screening at days 7 and 30 following TRUSP determined whether the patients experienced infectious complications (Additional file 4) or adverse drug reactions based on pre-determined criteria.
Outcomes and definitions
The primary outcome was to compare the rate of infection following TRUSP in subjects with and without CR-GNB. Secondary objectives included determination of risk factors for infection and antimicrobial resistance traits of rectal swab isolates. Infectious complications were clinically defined as 1) uncomplicated urinary tract infection (UTI): dysuria, urgency, frequency or hematuria without fever and with or without pyuria (> 5 white blood cells per high-powered field or positive leukocyte esterase on urine dipstick) or bacteriuria (≥ 10 5 colony-forming units/mL); 2) complicated UTI: fever, flank pain, nausea or vomiting with or without pyuria and bacteriuria; 3) urosepsis: criteria for sepsis, severe sepsis, and septic shock [21] were combined and categorized as urosepsis.
Statistical analysis
Analyses were performed with SAS version 9.3 (SAS Institute Inc., Cary, NC) and R version 3.3 (R Foundation for Statistical Computing, Vienna, Austria). Categorical variables were described by percentages and compared using Chi-square or Fisher exact tests as appropriate. Continuous variables were described by means and evaluated using Student t-test. A p-value <0.05 was considered statistically significant. Our initial goal was to enroll 1700 patients, and have enough patients in each group to obtain a 95% confidence interval for the difference in the complication rates between the two groups with a margin of error of, at most, 2%.
Results
Clinical characteristics
Five hundred ten (90.6%) patients were included in the analysis (Fig. 1 ). 24 patients underwent more than one Table 1 . In this cohort, 430 (84.3%) had CS-GNB and 80 (15.7%) had CR-GNB on rectal swab culture. Univariate analysis demonstrated that patients with CS and CR rectal flora were similar except that a history of urinary tract infection was more common in CR patients (p = 0.004). Similar results were observed in the per-protocol population. (Data not shown).
Microbiological characteristics
Of the 80 patients with CR-GNB, 76 (95%) harbored Escherichia coli, 2 (2.6%) Pseudomonas aeruginosa, 1 (1.2%) Citrobacter freundii and 1 (1.2%) Klebsiella pneumoniae. The antimicrobial susceptibility profiles of the CR-E. coli isolates are shown in Fig. 2 . Using the Centers for Disease Control and Prevention (CDC) definitions [22] to classify the bacteria, 62 (79.5%) were multidrugresistant (MDR), 17 (21.5%) were not MDR, and only 12 (15.2%) were resistant to ciprofloxacin alone. Of the MDR E. coli, 12 (15.2%) were extended-spectrum betalactamase producers (ESBLs). Interestingly, of the 24 patients who underwent two biopsies during the study period, the ciprofloxacin susceptibility status of 23 patients remained the same, while one patient who originally had CR-GNB had CS-GNB on subsequent culture. The antimicrobial prophylaxis regimens received are listed in Table 2 . Oral regimens were used for 61 (76.3%) of the 80 patients harboring CR-GNB. Twentyfour patients with CS-GNB received prophylaxis with ciprofloxacin plus another empiric antimicrobial agent; likewise, 2 with CR-GNB received prophylaxis with two non-FQ agents directed by rectal flora susceptibility.
Infectious complications
The clinical characteristics stratified by infectious outcomes for the ITT and the per-protocol patients are infections occurred in the per-protocol patients. There was no statistically significant difference in the rate of infections (CS = 1.5%; CR =3.9%; p = 0.337) between the two groups. Additionally, there were no statistically significant differences in the efficacy of the prophylactic regimens used. (Data not shown).
The characteristics of the 9 patients who developed infectious complications are shown in Table 6 . All infections occurred in patients who received single drug targeted prophylaxis. Infectious complications occurred in 6 (66.7%) patients within 7 days and in 3 (33.3%) patients at 8, 11, and 13 days, respectively. The 5 patients with uncomplicated UTIs were managed as outpatients, 4 with and 1 without antimicrobial therapy; those with complicated UTIs or sepsis were managed with antimicrobial therapy as inpatients for 1-5 (mean 2.6) days.
All patients recovered without sequelae. There were no drug-related adverse events. None of the 26 patients in the ITT group who received augmented prophylaxis developed infectious complications.
Three (33.3%) of the 9 patients with infections were culture negative. Of the 6 patients with positive cultures, 3 (2 ciprofloxacin and 1 amikacin) were prophylaxis failures, i.e. the infecting bacteria were susceptible to the prophylactic drug they received. One patient who received ciprofloxacin was infected with bacteria with a MIC that was intermediate to ciprofloxacin and 2 patients, one who received trimethoprim/sulfamethoxazole and one who received ciprofloxacin, broke through with organisms fully resistant to these drugs.
Discussion
With empiric single drug antimicrobial prophylaxis for TRUSP the hospitalization rate for infections is 0 to 6.3%. 2 Two approaches to address this have been developed. Empiric augmented prophylaxis has shown initially promising results. However, it is often influenced by local hospital antibiograms, fails to assess the rectal source of the post-biopsy infections, and its use will likely be directly related to increasing antimicrobial resistance. Alternatively, rectal swab cultures can 1) determine the population of fluoroquinolone-resistant (FQR)-GNB in the rectal flora, 2) identify specific patients with FQ -GNB and 3) guide targeted single drug and augmented prophylaxis [7, 14, 16, 19, 23, 24] . The presence of FQ-R bacteria in the rectal flora constitutes a five-fold increase in the rate and potential severity of post-biopsy infections in patients receiving empiric fluoroquinolone prophylaxis [25] . This finding supports the utilization of pre-biopsy rectal cultures to identify patients at increased risk and to select targeted prophylaxis that is most likely to be effective. These principles were supported by this prospective cohort study, which showed a very low, i.e. 0.6%, sepsis rate and equivalent infectious complication rates among patients with CR-GNB or CS-GNB rectal flora who received targeted prophylaxis per our protocol.
In our study, the FQ resistance rate was 15.7%. We agree with Van Besien et al. [25] who stated that the benefit of targeted prophylaxis depends on local FQ-R prevalence rates. A randomized, blinded trial would subject the approximately 20% of patients who harbor FQ-R flora and receive FQ prophylaxis to the known 5-fold higher risk of infectious complications [25] . Similarly, empiric augmented prophylaxis could also subject patients to ineffective antimicrobial prophylaxis. For example, gentamicin is frequently used for augmented prophylaxis, but gentamicin resistance was present in 20% of the bacteria isolated from our patients with CR-GNB rectal flora (Fig. 2) . Our infectious complication rate in the per-protocol patients of 1.9% improved upon the 2.6% infection rate prior to the introduction of this protocol [14] . We used very stringent criteria: inclusion of all patients with symptoms of urinary tract infection irrespective of urine or blood cultures and phone screening at 7-and 30-days. Indeed, of the 9 patients identified, 3 had negative cultures before antimicrobial therapy was initiated and 3 were negative at 7 days but positive within 30 days. More importantly, only 4 (0.8%) had significant clinical infections and only 2 were culture-proven, febrile UTI (0.2%) and sepsis (0.2%).
Of the 9 patients with infections, only 3 had prior exposure to fluoroquinolones, a rate similar to those who did not become infected. Of the 6 patients with positive cultures, 3 were prophylaxis failures, i.e. the infecting bacteria was susceptible to the prophylactic drug given, (ciprofloxacin 2, and amikacin 1). Since all of these patients received their prophylaxis per protocol, we cannot implicate noncompliance of the patient or medical error. Breakthrough infections were probably due to excessive inoculum at the time of biopsy and/or an unrecognized host risk factor(s). Three patients were infected with bacteria with antimicrobial susceptibility breakpoints that showed resistance whereas the pre-biopsy rectal bacteria were susceptible. This could be due to sampling error of the rectal flora, lack of detection on the selective media or increasing antimicrobial resistance between the time of the culture and the biopsy. Although incorporating a lower concentration of ciprofloxacin into the screening media may have rendered the two rectal cultures with intermediate susceptibility ciprofloxacinresistant, this extremely low incidence in our opinion would not support lowering the ciprofloxacin concentration in the screening media in our population.
Of the 6 culture-proven infections, the bacteria were multidrug resistant in 5, and of these, 2 were ESBLs. Williamson et al. noted similar results [26] . We identified trends in risk factors, e.g. history of UTI, however the incidence of infections was too low to achieve statistical significance [12, 24, [27] [28] [29] .
This study is limited in that it was a single institution study and, for ethical reasons, was not blinded or controlled. Erectile dysfunction, a potential complication of TRUSP, was not evaluated, but it may occur as a result of inflammation induced by infection [30] . Thus, targeted prophylaxis could have other indirect benefits. Larger, multicenter studies are necessary to study this approach and its generalizability.
Additionally, this study does not claim superiority to empiric augmented prophylaxis in terms of infection reduction. However, it is likely that antimicrobial prophylaxis based on real time sensitivity data will be more durable and will likely outperform empiric prophylaxis as bacterial resistance inevitably increases. It is possible that more extended use of augmented prophylaxis or use of multiday therapy [16, 29, 31, 32] would have reduced our infectious complications further, but adherence to the guidelines of antimicrobial stewardship favors limited, single drug targeted prophylaxis for most patients.
